Treatment of Acute Toxoplasmosis in Pregnancy: Influence in the Mother-to-Child Transmission

Bártholo, Bárbara B. G. Raskovisch; Monteiro, Denise Leite Maia; Rodrigues, Nádia Cristina Pinheiro; Trajano, Alexandre J. B.; Jesús, Nilson R. de; Cardoso, Fernanda Graziella; Souza, Flavio Monteiro de; Werner, Heron; Júnior, Edward Araujo

doi:10.1016/j.jogc.2020.04.021

Cited by 1 publication

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In studies investigating the efficacy of treatment, it was reported that parasite transmission from the mother to the child was higher in untreated pregnant women, and spyramicine prophylaxis was found to be effective for preventing CT. In addition, it has been shown that early diagnosis and treatment can reduce the mother-to-child transmission of the parasite, and can also reduce the disease’s severity in the infected fetus [ 18 , 20 , 25 , 26 ]. However, the SYROCOT study did not find robust evidence for a link between early treatment and decreased risk of CT [ 14 ].…”

Section: Discussionmentioning

confidence: 99%

Toxoplasmosis: A Timeless Challenge for Pregnancy

et al. 2023

View full text Add to dashboard Cite

This study aimed to evaluate the prevalence of toxoplasmosis in pregnant women, as well as the general characteristics, clinical and laboratory findings, and pregnancy and fetal outcomes of pregnant women diagnosed with acute toxoplasma infection (ATI). The toxoplasma IgM, IgG, and IgG avidity test results of pregnant women who applied to our referral hospital between January 2016 and June 2022, and among them, those diagnosed with ATI, were analyzed. The 119 patients diagnosed with ATI during this time period were included for further analysis. The prevalence of toxoplasmosis in pregnant women was found to be 46.2%, and the rate of ATI was 4%. The total mother-to-child transmission rate was 5% (5/101). Congenital toxoplasmosis (CT) was observed in 1 (1.1%) child of the 87 pregnant women who received spiramycin prophylaxis, though it was found in 4 (30.8%) of the children of the 13 untreated mothers. With respect to prenatal treatment, CT rates were significantly higher in the children born to untreated mothers (p = 0.001). In conclusion, although toxoplasma seroprevalence was found to be high in our region, there was a paucity in diagnosis, follow-up, and treatment. Our findings support that prenatal spiramycin prophylaxis is effective in preventing the transmission of parasites from mother to child.

show abstract